Médunik Canada once again receives Notice of Compliance from Health Canada for Ruzurgi® (amifampridine) following review ordered by court ruling

BLAINVILLE, Quebec (Canada) – June 29, 2021 – Médunik Canada is pleased to announce that Health Canada has reissued the approval (Notice of Compliance) for Ruzurgi® (amifampridine), for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients six years of age or older and has resumed supply in Canada.

Read more

Ruzurgi® Now Available to Canadian Lambert-Eaton Myasthenic Syndrome (LEMS) Patients

BLAINVILLE, Quebec (Canada) – September 25, 2020 – Médunik Canada, a pharmaceutical company dedicated to improving the health and quality of life of Canadians with rare diseases, is extremely pleased to announce that its new orphan disease product Ruzurgi® (amifampridine) is now commercially available to Canadian patients.

Read more

Médunik Canada Expands its Orphan Disease Portfolio by Receiving Market Authorization for Ruzurgi®

BLAINVILLE, Quebec (Canada) – August 18, 2020 – Médunik Canada, a pharmaceutical company dedicated to improving the health and quality of life of Canadians with rare diseases, is extremely pleased to announce that our orphan disease portfolio just expanded further with the recent addition of a new drug. Health Canada has issued a Notice of Compliance (NOC) for Ruzurgi® (amifampridine), a drug indicated for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in patients 6 years of age or older.

Read more

Medunik Canada signs an exclusive agreement with HRA pharma for commercialization of Lysodren® (mitotane) in Canada, for the treatment of inoperable adrenal cortical carcinomas

BLAINVILLE, QC (CANADA), January 16, 2019 — Medunik Canada, a company dedicated to improving the health and quality of life of Canadians living with rare diseases, is proud to announce the signing of a licensing and supply agreement with HRA Pharma. The agreement grants Medunik Canada exclusive commercial rights in Canada for Lysodren®, indicated for the treatment of inoperable functional and non-functional adrenal cortical carcinoma.  

Read more

Medunik Canada is pleased to announce the launch of NORD Founder Abbey Meyers’ memoir, “Orphan Drugs: A Global Crusade”

BLAINVILLE, QC (Canada) – February 16, 2016 – Medunik Canada, a Canadian pharmaceutical company specialized in orphan drugs, is pleased to announce the launch of Orphan Drugs: A Global Crusade, the memoir of Abbey Meyers, founder and past President of the National Organization for Rare Disorders (NORD). In anticipation of Rare Disease Day on February 29th, Medunik Canada would like to bring to light the hard work and commitment of orphan drug crusaders, like Ms. Meyers.

Read more